Market Intelligence, Preclinical Progress, and High-Purity Reagents for DNA Damage Response (DDR) and Synthetic Lethality Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for C16orf75/RMI2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Monomer) | Human RMI2 (C16orf75) Full-Length Protein; HEK293 Expressed, >95% Purity, Endotoxin <1 EU/µg, Sequence Verified. | View RMI2 Products |
| Antigen (Complex) | RMI2-RMI1 Heterodimer Complex; Co-expressed in HEK293 for native conformation, SPR/ITC Ready. | View RMI2 Products |
| Mutant Panel | RMI2 PPI-Deficient Mutants (e.g., F198A, W228A); Sequence Verified, For structure-activity relationship (SAR) studies. | View RMI2 Products |
| Gene Delivery | RMI2 Lentivirus Particles (CMV promoter); High titer (>10^8 TU/mL), Puromycin selection, for stable cell line construction. | View RMI2 Products |
| Gene Knockdown | Anti-RMI2 siRNA Set (3 pre-designed sequences); HPLC purified, validated for >80% knockdown efficiency. | View RMI2 Products |
| Benchmark Ab | Anti-RMI2 Recombinant Rabbit mAb; Sequence Verified, ChIP-grade, Suitable for Co-IP/Western. | View RMI2 Products |
| Related Target: BLM | RecQ-like Helicase (BLM); Core BTR complex partner; Required for RMI2 recruitment to DNA damage sites. | View BLM Products |
| Related Target: RMI1 | RMI1 (BLAP75); Obligate heterodimeric partner of RMI2; Essential for complex stability. | View RMI1 Products |
| Related Target: TOP3A | DNA Topoisomerase III-alpha; Catalytic component of BTR complex; Interacts via RMI2-RMI1 scaffold. | View TOP3A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Obligate Heterodimer Formation (RMI2-RMI1) | Pre-formed RMI2-RMI1 Complex Protein expressed in HEK293; Maintains native binding affinity without artificial linker sequences. |
| PPI Disruption Screening (Small Molecule/Peptide) | Wild-type vs. Mutant RMI2 proteins (Phe198, Trp228 binding hotspot mutants) available for differential binding assays. |
| Nuclear Localization & Function | High-titer Lentivirus for stable integration; Suitable for DR-GFP homologous recombination repair assays and synthetic lethality screening. |
| Complex Purity & Specificity | Endotoxin <1 EU/µg; Host cell DNA <10 pg/µg; Suitable for sensitive cellular assays and animal studies. |
| Off-target Liability Across RecQ Family | Ortholog and paralog panels (Human/Mouse/Cyno) with sequence-verified domain boundaries. |
| False Positives in PROTAC Screening | Precise Theoretical MW confirmation via Mass Spec limits off-target complex formation. |
Live C16orf75/RMI2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for C16orf75/RMI2 therapeutics is intensifying within the synthetic lethality space, with major players shifting focus from single-agent PARP inhibition to combination strategies targeting the BTR complex. As first-generation DDR inhibitors face resistance mechanisms, the next wave of R&D is targeting protein-protein interactions within the Holliday junction dissolution pathway. RMI2, as the stabilizing arm of the BTR complex, represents a novel vulnerability in BRCA-deficient and replication-stress-high tumors. Current R&D activity is concentrated in preclinical synthetic lethality programs and structure-guided PPI inhibitor discovery. While no RMI2-directed agent has yet entered Phase I, the target is increasingly prioritized in combination strategies alongside PARP inhibitors and platinum-based regimens to overcome acquired resistance in homologous recombination-proficient tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors (PPI) | Emerging Academic/Biotech | BRCA-mutant Ovarian, Breast, Prostate Cancers; Advanced Solid Tumors | PPI Disruption Assay (Need RMI2-RMI1 complex & mutants) |
| Peptide/Miniprotein Disruptors | Early-stage Ventures | Solid Tumors (High Replication Stress) | AlphaScreen/TR-FRET (Need high-purity WT vs mutant proteins) |
| PROTAC / Degrader | Targeted Protein Degradation Startups | Prostate Cancer, Breast Cancer (BRCA-mutant) | Ternary Complex Validation (Need Sequence Verified Proteins) |
| Synthetic Lethality Screens | Functional Genomics Consortia | Pancreatic, High-Grade Serous Ovarian | Stable Cell Line Generation (Need Lentivirus & siRNA) |
| Combination (PARPi) | Global Pharma | Ovarian Cancer, HR-deficient Cancers | Cell Viability Assays (Need pure Lentivirus for Stable Lines) |